We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.
- Authors
Dimopoulos, M A; Pouli, A; Zervas, K; Grigoraki, V; Symeonidis, A; Repoussis, P; Mitsouli, C; Papanastasiou, C; Margaritis, D; Tokmaktsis, A; Katodritou, I; Kokkini, G; Terpos, E; Vyniou, N; Tzilianos, M; Chatzivassili, A; Kyrtsonis, M C; Panayiotidis, P; Maniatis, A; Greek Myeloma Study Group
- Abstract
The combination of vincristine and doxorubicin administered as a continuous infusion via an indwelling catheter together with intermittent high-dose dexamethasone (VAD) is an effective primary treatment for patients with symptomatic multiple myeloma. In order to avoid the need for an indwelling catheter, which imposes logistic problems for outpatient administration, several phase II studies have explored the feasibility and efficacy of VAD-like outpatient regimens. We designed a prospective randomized study to compare the objective response rates of two VAD-like outpatient regimens as primary treatment for symptomatic patients with multiple myeloma.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Vol 14, Issue 7, p1039
- ISSN
0923-7534
- Publication type
Journal Article
- DOI
10.1093/annonc/mdg287